Women's Health

The Bottleneck in Women's Health Was Never the Drug

Investors are pitching women's health on a trillion-dollar productivity gap, but endometriosis still averages years to diagnose and roughly 85 percent of osteoporotic fracture patients never receive treatment for the disease that broke their bones. Both conditions have had effective treatments for decades. The bottleneck was never the drug; it's the recognition and referral gap venture capital has no way to fund.

By James T. · Updated August 26, 2026 · 8 min read

Scroll down for medical verification information & sources.

The pitch now being made to investors in women's health rests on a number. Closing the gap between how men's and women's conditions are treated would add roughly a trillion dollars a year to global economic productivity by 2040, according to a World Economic Forum analysis done with the McKinsey Health Institute, with about $300 billion of that recoverable in the United States alone. Venture money has heard the pitch. Women's health funding hit $2.6 billion in 2024, a 55 percent jump from the year before, and recent reporting on the sector describes executives and academics openly replacing the old moral appeals for women's health research with the profit motive, because federal research money has become less dependable.

The problem with the pitch is where the money lands. The trillion dollars does not hide in the molecule. It hides downstream, in the years a condition goes unrecognized and the moments after a diagnosis when treatment never starts. Two conditions show the pattern with unusual clarity, and they matter because both now have investors circling and both have been treatable for a long time. Endometriosis takes years to diagnose. Osteoporosis goes untreated in most of the patients who fracture from it. The bottleneck was never the drug. It was the last mile.

A disease that waits for a surgeon's confirmation

Endometriosis, in which tissue similar to the uterine lining grows elsewhere in the body, affects roughly one in ten women of reproductive age. It causes chronic pain, heavy bleeding, and in many cases infertility. Its diagnosis, historically, has required laparoscopic surgery, and the road to that surgery is remarkably long. In a 2025 review of studies from the United States, Canada, and Europe, average delays from first symptoms to diagnosis ranged from two years to twelve, with many studies landing near seven. The first symptoms typically appear in the teenage years, which means a condition that starts at sixteen is often confirmed around twenty-five, after a decade of pain that gets called period pain.

The delay is not neutral. It compounds. A U.S. claims study of nearly 12,000 patients found that health care costs before diagnosis climbed with every year of waiting, from about $21,500 for patients diagnosed within a year to $34,500 for those who waited three to five years, with more emergency visits and hospitalizations along the way. A Japanese study linked longer delays to more advanced disease at diagnosis. The economics of the delay are perverse in exactly the way investors should notice: the health system pays more, the patient suffers more, and the eventual care is harder and later. Money arriving at the drug stage does not touch any of this.

Nor is the delay a mystery that needs new science. It is the product of an ordinary clinical sequence: pain that is reported early and normalized early, symptoms that overlap with common complaints, referral patterns that treat a teenage complaint as low priority, and a confirmatory test that has historically meant surgery. Every step is defensible on its own, which is why the whole has been so hard to change. The new capital in endometriosis is aimed at treatments and at non-invasive diagnostics, but the patients those products need to find are still ten years upstream, having already learned to describe their own pain as normal.

A fracture that should start a treatment, and does not

Osteoporosis shows the same gap at the opposite end of the timeline. Here the diagnosis is easy, the treatment is decades old, and the system still drops most patients. The moment of maximum medical motivation is a broken hip or a crushed vertebra, and that moment is being wasted. In a nationwide Swiss claims analysis covering 2021 to 2023, 88 percent of hip fracture patients and 77 percent of vertebral fracture patients received no osteoporosis medication within six months of the fracture. An Italian study of nearly 24,000 hip fractures found 87.8 percent untreated in the same window. The pattern repeats across countries and has for years.

The consequences are not subtle. Untreated patients refracture at meaningfully higher rates, and their mortality is roughly double that of treated patients. The Swiss data found that the single strongest predictor of getting treated was having had a bone density scan, a test ordered far too rarely even after a fracture. A hip fracture is treated as an orthopedic event and then the patient is sent home, when the fracture is the clearest possible signal that a chronic bone disease is now active. The system responds to the fall. It does not respond to the disease that made the fall catastrophic.

The money is arriving upstream of the problem

The capital now flowing into women's health is real and concentrated. Menopause care has become one of the fastest growing segments in health care investment, with companies like Midi Health raising $100 million and the category growing around 13 percent a year. Exits have validated the sector, with disclosed exit value across two decades crossing $100 billion. Dedicated funds keep forming. What the capital has not solved is the part of the pipeline between the product and the patient, because that part runs through primary care appointments, pelvic pain that gets normalized, bone scans that never get ordered, and a federal research apparatus that is shrinking at the same moment the private market is expanding.

That last point cuts both ways, and both sides of the funding debate deserve their strongest case. The administration has cancelled hundreds of grants in reproductive health and related fields, wound down parts of the research infrastructure built for women's health, and slowed overall grant spending; its stated rationale is that federal research needed reordering and that some spending was misplaced. Researchers argue the retreat leaves exactly the long-horizon work, cohort studies, registries, safety data, that venture capital will never fund because it has no five-year exit. This analysis takes no position on the contested questions about federal research priorities. The structural point stands regardless: private money funds products. It does not fund the recognition problem, and the recognition problem is where the patients are lost.

The World Economic Forum's own framework said as much. Its report identified four levers for closing the gap: science, data, care delivery, and investment. Investment is one of four, and the other three all operate at the last mile. The report also noted that only about 5 percent of the women's health burden comes from conditions unique to women; the rest comes from conditions both sexes get that are recognized later and treated worse in women. That is a delivery problem with a stock market attached to it.

The returns depend on the referral

For the investors taking the pitch seriously, the last mile is not a charity problem. It is a utilization problem. A drug for endometriosis cannot earn back its development cost if the patients who need it are still being told their pain is normal in their early twenties. A bone drug cannot prevent the next fracture if the first fracture does not trigger a prescription. The trillion-dollar opportunity assumes the health system converts newly funded products into treated patients, and that conversion has been failing for decades in exactly the conditions now being pitched as the opportunity.

The capital itself, impressive as the recent numbers are, remains thin in proportion. Women's health attracts somewhere around 5 to 6 percent of global health care research and investment dollars despite women being half the population. Many companies in the sector stall between early funding and the late rounds that require billion-dollar comparisons, a commercial valley of death that has nothing to do with science and everything to do with buyers who lack the framework to evaluate the products, because the conditions were barely taught in their own clinical training. Investors are being asked to bet on a market whose demand side, the doctors who order and the plans that pay, is the least prepared part of the chain. That is a last-mile problem wearing a venture capital suit.

The encouraging part is that the last mile is well mapped. Fracture liaison programs, in which a coordinator ensures every fracture patient gets a bone assessment, close most of the osteoporosis gap in the hospitals that run them. Non-surgical diagnostic pathways for endometriosis are advancing. The frustrating part is that none of this is new. The gap was never mysterious, and it was never mainly about treatment. It was about the years before diagnosis and the silence after the fracture, the ordinary administrative and clinical frictions where a trillion dollars a year quietly escapes. Money talks, the pitch says. It has been talking for a while now, and the patients it is meant to reach are still waiting at the wrong end of the system.

Primary sources

The STAT report by Elizabeth Cooney for the profit-motive framing, the reverse-pitch context, and the WEF productivity figures.
The World Economic Forum and McKinsey Health Institute analysis for the $1 trillion and $300 billion estimates and the four-lever framework.
The 2025 targeted literature review presented at ISPOR and the U.S. claims study by Surrey and colleagues for the endometriosis delay ranges and cost data, and the Italian hip fracture study in Drugs & Aging for the osteoporosis treatment gap figures.

Written by James T.

Do you disagree with any of the medical statements in this article? Email medical_disputes@mavengity.com with your feedback.

This is general analysis, not medical advice, and not investment advice or a recommendation regarding any security; questions about symptoms and treatment belong with your own care team. Sources include STAT and the World Economic Forum. Mavengity is editorially independent.

Vaccines

The Cleverest Part of the Shingrix Study Is Also Its Ceiling

An Oxford study using the 2017 Shingrix approval date as a natural experiment found 9 percent less cardiovascular disease in recipients versus the older shingles vaccine. The design elegantly removes the usual healthy-vaccinee bias, but it is still an observational study, and a randomized Danish trial of 162,000 people will settle the question in 2027.

The Bottleneck in Women's Health Was Never the Drug

A disease that waits for a surgeon's confirmation

A fracture that should start a treatment, and does not

The money is arriving upstream of the problem

The returns depend on the referral

Primary sources

More from Healthcare & Medical

The Cleverest Part of the Shingrix Study Is Also Its Ceiling

New York's Aid-in-Dying Law Runs on Doctors the State Does Not Have

Measles Disappeared for So Long That Its Danger Became Hard to Believe

One in Five People Carries a Heart Risk Their Doctor Never Tested For

Four Years After Dobbs, the Data Refused to Keep Score

The Sound in the ICU That Has No Column in the Chart

Medicaid Cuts Are Closing the Last Mile of Rural Care First

In Long-Term Care, the Screening Decision Is Made by Logistics

Hospital Diversion Software Is Only as Strong as Its Most Human Link

The SNAP Soda Ban Cut Soda, Not Sugar

Patients Are Not Really Asking for a Handshake

A One-Time Gene Therapy Has No Off Switch

Nursing Schools Can Admit Students They Cannot Place

Moderna's Cancer Vaccine Win Is Bigger Than Moderna

The FDA Is Writing AI Rules for a Technology That Won't Hold Still

In a Duchenne Trial, the Smallest Decisions Carry the Biggest Weight

The Case for Eating Less Protein Comes From Bodies Whose Problem Is Not the One Older Humans Have

Where Muscle Dysmorphia Sits in the DSM Decides Who Gets Treated for It

The Money That Outlasts Politics Has Politics of Its Own

The Diagnostic Miracle That Sold the Medical Chatbot Is the Easiest Part of Its Job

An Open-Label Extension Describes Only the Patients Who Stayed in It

In Cancer's Biggest Year, the Hard Problem Moves From Discovery to Production

The Melanoma Vaccine That Can't Be Made Until After Surgery

The New FOP Drug Saves What the Disease Hasn't Taken Yet

Brain Organoids That Live Five Years Are Outrunning the Ethics Debate

In a Four-Boy Trial, the Riskiest Dose Went to the Last Patient

Medical Bills Fed a $1.1 Billion Payout to a Nonprofit Health System

Bariatric Surgery's Bill Arrives Years Later

One Sentence in Public Health's Accreditation Standards Became a Political Fight

Exam Scores Are Deciding Who Wins the AI Doctor Race

A New Virtual Cell Model Is an Option, Not an Answer

A Drop in Private Equity Deals Is Not the Same as Less Consolidation

The Medicaid Pilot That Nearly Died Before the Savings Showed Up

Fathers Bear the Cost of a Benefit Everyone Else Collects

The $11 Insulin Pen Almost Nobody Is Buying

What a Trial of a Hundred Patients Cannot Tell You About Risk

What the Growing Wait for Cancer Treatment Is Really Made Of

The Hard Question Behind the Vykat Safety Warning: Was It the Drug, or the Disease?

As Gene Therapy for Deafness Advances, the Real Question Is How It's Offered

How Medicare's Weight-Loss Drug Program Could Become Its Own Argument Against Coverage

Why People Who Still Qualify Keep Losing Their Medicaid

The Trouble With "Targeted" Radiation: It Still Hits the Kidneys on the Way to the Tumor

Why China Is Reining In the Very Clinical-Trial System the U.S. Wants to Copy

When a Life-Sustaining Drug Depends on a Single Factory

Boston Mastered Biotech's First Era. One Founder's Move to California Is a Question About Its Second

One Year After the CDC Shooting, the Danger to Public Health Has Shifted From the Diseases It Fights to the Trust It Needs

The NIH Plans to Bar Visa-Holding Scientists From a Career-Making Grant. The Real Cost Is Retention, and It's Easy to Miss

The FDA Cleared a Melanoma Drug It Twice Rejected. The Approval Defers the Hard Question to a Trial Still Running

A Relabeling Meant to Invite Competition Gave an Old AbbVie Drug Seven More Years Before Price Negotiation

Tau May Harm Neurons by Running Their Mitochondria in Reverse. That's a Genuine New Lead, and a Familiar Long Shot

A Closed-Door Clinical-AI Demo Day With Regulators Shows Why Industry Engagement Is Both Necessary and Risky

Erica Schwartz Is Confirmed to Lead the CDC, on the Strength of What She Declined to Promise

The Orphan-Drug Exemption Was Built for Small Markets. It Now Protects Blockbusters, Which Is Why It Guts Medicare's Savings

In Prostate Cancer, a Better Test Finds Fewer Cancers. The MRI-Versus-Biopsy Debate Is Really About Overdiagnosis

Prehabilitation for Frail Heart-Transplant Candidates Reframes Eligibility as a Movable Threshold, Not a Fixed Trait

Medicare Is Tightening Breakthrough-Device Payments and Speeding Their Coverage. Understanding the Difference Explains the Policy.

The 2026 Cyclospora Outbreak Records Its First Deaths, and Its Source, Scale, and Danger Are Each Less Simple Than They Appear

A Senate Bill Blocks Political Control of Research Grants. The Real Question Isn't Whether Politics Belongs, but Where.

The FDA's Advisers Backed a Drug They Couldn't Fully Interpret and Rejected One They Called a "Mirage." The Difference Is Trust.

Syphilis Is Curable With a Cheap, 80-Year-Old Shot. Every Reason It's Spreading Is a System Failure.

A Diabetes Group Fought for Editorial Independence in 2015. Now It's Suppressing Its Own. The Difference Is Who It Costs.

The FDA Halted Every Trial Using One Vector and Restored Only One. The Inconsistency Is More Defensible Than It Looks.

Novo Nordisk's Drug Lowered Inflammation Perfectly. It Prevented Zero Heart Attacks. That Gap Is Why Outcomes Trials Exist.

Medicaid's New Exemption Is for People Too Sick to Work. Claiming It Requires the Very Capacity Being That Sick Takes Away.

Is America's Drug-Supply Vulnerability China's Fault or Our Own? The Answer Is Both, and the Order Matters.

Oil Shocks Make Some Medicines Pricier. The Weak Point Isn't Shipping, It's the Chemistry Itself.

A Judge Declined to Pause Medicaid's New Work Rule. He Didn't Decide Whether It's Lawful, and That Distinction Is the Whole Story.

Cassidy Traded His Vote for Assurances Once Before. Those Reportedly Broke. He Just Did It Again.

A Long Hospital Stay Doesn't Pause a Child's Development. It Spends a Part That Doesn't Come Back.

A Non-Opioid Painkiller Reportedly Outperformed an Opioid. Before the IPO, It's Worth Asking What "Outperformed" Means.

Half of Life-Science PhDs Now Leave for Industry. A New Program Redesigns the Degree to Match.

General AI Outscored Clinical AI on Medical Tests. That Says Less About the AI Than About the Tests.

China Now Runs More Early-Stage Drug Trials Than the U.S. America's Distinctive Answer Isn't Scale. It's a System That Remembers Every Patient for Life.